Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma

Peter Martin, Zhengming Chen, Bruce D. Cheson, Katherine S. Robinson, Michael Williams, Saurabh A. Rajguru, Jonathan W. Friedberg, Richard H. van der Jagt, Ann S. LaCasce, Robin Joyce, Kristen N. Ganjoo, Nancy L. Bartlett, Bernard Lemieux, Ari VanderWalde, Jordan Herst, Jeffrey Szer, Michael H. Bar, Fernando Cabanillas, Anthony J. Dodds, Paul G. MontgomeryBryn Pressnail, Tricia Ellis, Mitchell R. Smith, John P. Leonard

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

Despite the long history of bendamustine as treatment for indolent non-Hodgkin lymphoma, long-term efficacy and toxicity data are minimal. We reviewed long-term data from three clinical trials to characterize the toxicity and efficacy of patients receiving bendamustine. Data were available for 149 subjects at 21 sites. The median age was 60 years at the start of bendamustine (range 39–84), and patients had received a median of 3 prior therapies. The histologies included grades 1–2 follicular lymphoma (FL; n = 73), grade 3 FL (n = 23), small lymphocytic lymphoma (n = 20), marginal zone lymphoma (n = 15), mantle cell lymphoma (n = 9), transformed lymphomas (n = 5), lymphoplasmacytic lymphoma (n = 2) and not reported (n = 2). The median event-free survival was 14·1 months. Nine of 12 attempted stem cell collections were successful. With a median follow-up of 8·9 years, 23 patients developed 25 cancers, including 8 patients with myelodysplastic syndrome/acute myeloid leukaemia. These data provide important information regarding the long-term toxicity of bendamustine in previously treated patients. A small but meaningful number of patients achieved durable remissions following bendamustine. These rigorously collected, patient-level, long-term follow-up data provide reassurance that bendamustine or bendamustine plus rituximab is associated with efficacy and safety for patients with relapsed or refractory indolent non-Hodgkin lymphoma.

Original languageEnglish
Pages (from-to)250-256
Number of pages7
JournalBritish Journal of Haematology
Volume178
Issue number2
DOIs
StatePublished - Jul 2017

Keywords

  • chemotherapy
  • haemotoxicity
  • lymphomas

Fingerprint Dive into the research topics of 'Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma'. Together they form a unique fingerprint.

  • Cite this

    Martin, P., Chen, Z., Cheson, B. D., Robinson, K. S., Williams, M., Rajguru, S. A., Friedberg, J. W., van der Jagt, R. H., LaCasce, A. S., Joyce, R., Ganjoo, K. N., Bartlett, N. L., Lemieux, B., VanderWalde, A., Herst, J., Szer, J., Bar, M. H., Cabanillas, F., Dodds, A. J., ... Leonard, J. P. (2017). Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma. British Journal of Haematology, 178(2), 250-256. https://doi.org/10.1111/bjh.14667